Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of huCART19-IL18 Cells in Patients With Relapsed or Refractory CD19+ Cancers

NCT04684563 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT04684563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04684563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of huCART19-IL18 Cells in Patients With Relapsed or Refractory CD19+ Cancers
Lead sponsor
University of Pennsylvania
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 6, 2021
Completion date
May 31, 2036
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, chronic lymphocytic leukemia, non-hodgkin lymphoma